Healthcare

HB 4610 allows terminally ill patients in West Virginia to access experimental, individually tailored medical treatments (like gene therapies) when standard FDA-approved options have been exhausted. It defines "eligible patients" as those with life-threatening illnesses who have consulted a physician, considered all approved treatments, and provided written consent detailing treatment risks and alternatives. Key provisions require healthcare providers to document patient eligibility, obtain specific informed consent covering potential outcomes, and prohibit debt collection from estates if a patient dies during treatment. The bill also protects healthcare providers from sanctions for offering these treatments and clarifies that it does not affect health insurers' obligations to cover clinical trial participation.

HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.